Full history for every metric is available with a Kvantra account
Akoya Biosciences, Inc. (AKYA)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 42 | 42 | 55 | 75 | 97 | 82 | 80 |
| Operating profit | $m | -47 | -39 | |||||
| Net profit | $m | -15 | -17 | -43 | -71 | -63 | -55 | -48 |
| EPS reported | $ | -1.12 | -0.97 | |||||
| Operating cashflow per share | $ | -0.89 | -0.89 | |||||
| Capex per share | $ | 0.05 | 0.05 | |||||
| FCF per share | $ | -0.94 | -0.94 | |||||
| Free cash flow | $m | -47 | -32 | |||||
| Net debt | $m | 41 | 49 | |||||
| Book value equity | $m | 8 | -6 | |||||
| Book value per share | $ | 0.15 | -0.12 | |||||
| Number of shares | m | 49.42 | 49.66 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 14.90 | -10.94 | |||||
| P/S LTM | x | 1.39 | 0.81 | |||||
| P/FCF LTM | x | -2.43 | -1.99 | |||||
| EV/EBITDA LTM | x | -5.00 | -3.82 | |||||
| EV/Sales LTM | x | 2.27 | 1.42 | |||||
| Earnings Yield LTM | % | -48.92% | -86.85% | |||||
| FCF Yield | % | -41.14% | -50.19% | |||||
| Quality | ||||||||
| ROE | % | -728.97% | -180.44% | |||||
| ROIC | % | -47.28% | -47.28% | |||||
| Operating margin | % | -57.22% | -57.22% | |||||
| Gross margin | % | 58.62% | 58.62% | |||||
| FCF/Sales | % | -57.01% | -57.01% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -15.48% | -14.55% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.55 | -0.39 | |||||
| Net Debt/EBITDA | x | -1.95 | -1.95 | |||||
| EBIT/Net interest | x | -4.48 | -4.48 | |||||
| Net debt/market cap | % | 36.35% | 75.95% | |||||
| Net debt/Equity | x | 5.42 | -8.31 | |||||
| Gross debt/equity | x | 11.08 | -14.22 | |||||
Company overview
Akoya Biosciences, Inc. is a prominent life sciences technology firm dedicated to furnishing advanced spatial biology solutions. The company's mission is to significantly advance both discovery and clinical research across numerous global regions, including North America, Asia Pacific, Europe, the Middle East, and Africa. Their core product lineup features the PhenoCycler instrument, a compact benchtop fluidics system designed to integrate seamlessly with a microscope for automated image acquisition. Complementing this is the PhenoImager platform, which empowers researchers to intricately visualize, analyze, quantify, and characterize cells directly within diverse tissue samples—such as fresh frozen or FFPE sections and tissue microarrays—through an efficient, automated, and high-throughput process. Akoya also supplies the essential reagents for these PhenoCycler and PhenoImager systems, alongside providing specialized biopharmaceutical services. Beyond hardware, Akoya offers a robust suite of software tools. Proxima serves as a cloud-based platform for the secure storage, comprehensive analysis, and collaborative sharing of spatial data. For image interpretation, the inForm Tissue software delivers automated analysis to precisely visualize and quantify biomarkers within tissue sections. Further streamlining data workflows, Phenoptr facilitates the consolidation and in-depth analysis of output tables generated by inForm. Finally, phenoptrReports is a user-friendly software application that generates intuitive reports and visualizations from phenoptr output, presented via an easy-to-navigate graphical user interface. Established in 2015, Akoya Biosciences maintains its corporate headquarters in Marlborough, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Akoya Biosciences, Inc. (AKYA)
Akoya Biosciences, Inc. is a prominent life sciences technology firm dedicated to furnishing advanced spatial biology solutions. The company's mission is to significantly advance both discovery and clinical research across numerous global regions, including North America, Asia Pacific, Europe, the Middle East, and Africa. Their core product lineup features the PhenoCycler instrument, a compact benchtop fluidics system designed to integrate seamlessly with a microscope for automated image acquisition. Complementing this is the PhenoImager platform, which empowers researchers to intricately visualize, analyze, quantify, and characterize cells directly within diverse tissue samples—such as fresh frozen or FFPE sections and tissue microarrays—through an efficient, automated, and high-throughput process. Akoya also supplies the essential reagents for these PhenoCycler and PhenoImager systems, alongside providing specialized biopharmaceutical services. Beyond hardware, Akoya offers a robust suite of software tools. Proxima serves as a cloud-based platform for the secure storage, comprehensive analysis, and collaborative sharing of spatial data. For image interpretation, the inForm Tissue software delivers automated analysis to precisely visualize and quantify biomarkers within tissue sections. Further streamlining data workflows, Phenoptr facilitates the consolidation and in-depth analysis of output tables generated by inForm. Finally, phenoptrReports is a user-friendly software application that generates intuitive reports and visualizations from phenoptr output, presented via an easy-to-navigate graphical user interface. Established in 2015, Akoya Biosciences maintains its corporate headquarters in Marlborough, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free